OTC Markets OTCQB - Delayed Quote USD

Bioxytran, Inc. (BIXT)

0.1350

-0.0017

(-1.24%)

At close: June 5 at 8:00:00 PM EDT

Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes

Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments BOSTON, MASSACHUSETTS, June 03, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran’s Science Advisor Prof. Avraham Mayevsky’s book titled The Mongolian Gerbil Brain: Mitochondrial Function, Vasculature, and Pathophysiological States was publishe

GlobeNewswire 5 days ago

BIXT
-1.24%
Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission

PHM23 was one of a handful of molecules chosen by the universityBird Flu helping PHM23 gain awareness of broad-spectrum activity at a university level BOSTON, MASSACHUSETTS, May 21, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing breakthrough antiviral treatments, announced that the University of Georgia confirmed the antiviral PHM23 was to be included amongst other drug candidates in the Universities grant submission to t

GlobeNewswire 18 days ago

BIXT
-1.24%
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies

GlobeNewswire 19 days ago

GOSS

RGBP

RGBPP
Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies

GlobeNewswire 20 days ago

SEVCF

TZUP

NCSM
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M

BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful completion of the dose optimization of its antiviral drug ProLectin-M in a randomized double-blind placebo-controlled trial. Preliminary results are expected, with full data submission to the FDA under Bioxytran’s active Investigational New Drug (IND) clinical trials for ProLectin-M. Key

GlobeNewswire 27 days ago

BIXT
-1.24%
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire last month

BNZI

BNZIW

SEVCF
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases - Leading drug candidate ProLectin-M targets galectins in viral infections including bird flu like viruses BOSTON, MASSACHUSETTS, April 11, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel therapies targeting hypoxia and mitochondrial dysfunction, today highlighted the historical and s

GlobeNewswire last month

BIXT
-1.24%
Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

GlobeNewswire 2 months ago

GOVX

GOVXW

PLAB
Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens

In Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the signing of a Non-Disclosure Agreement (NDA) with the Board of Regents of the University System of Georgia by and on behalf of the University of Georgia. The collaboration will focus on evalua

GlobeNewswire 2 months ago

BIXT
-1.24%
Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions

New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks BOSTON, MASSACHUSETTS, March 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, unveiled a potential game-changer in the fight against Highly Pathogenic Avian Influenza (HPAI), commonly known as Bird Flu. This innovative water-soluble galecti

GlobeNewswire 2 months ago

BIXT
-1.24%
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

GlobeNewswire 3 months ago

HGRAF

AEMD

GOSS
Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development

- Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced that it has entered into a common stock purchase agreement (the “SPA”) with TRITON FUN

GlobeNewswire 4 months ago

BIXT
-1.24%
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 4 months ago

IPWR

NZAUF

ELRRF
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its preprint article titled “Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients” (the “Article”) authored by Dr. Adesuy

GlobeNewswire 4 months ago

BIXT
-1.24%
Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting

BOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced a well-attended Techwatch Light meeting hosted by the Biomedical Advanced Research and Development Authority (BARDA) to introduce the company to the government, and help facilitate and direct the Company’s approach toward finding p

GlobeNewswire 4 months ago

BIXT
-1.24%
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 6 months ago

UCAR

OPWEF

BIXT
-1.24%
NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces NRx Pharmaceuticals (NASDAQ: NRXP) will appear on the Emerging Growth Conference today in response to multiple requests and investor demand. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Jonathan Javitt, M

GlobeNewswire 7 months ago

CIA

BIXT
-1.24%

NRXBF
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

MIAMI, Oct. 30, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 7 months ago

CIA

GOSS

STXPF
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 7 months ago

VOXR

BVAXF

CIA
Presenting on the Emerging Growth Conference 75 Day 2 on September 26

MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting

GlobeNewswire 8 months ago

ATWT

SEVCF

UMAC

Performance Overview

Return	BIXT	S&P 500 (^GSPC)
YTD	+50.17%	+2.02%
1-Year	+11.11%	+12.09%
3-Year	-32.50%	+45.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bioxytran, Inc. (BIXT)

Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes

Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens

Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Performance Overview